Please login to the form below

Not currently logged in
Email:
Password:

Xultophy

This page shows the latest Xultophy news and features for those working in and with pharma, biotech and healthcare.

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi wins EU approval for new diabetes combination Suliqua

same day as rival therapy Xultophy, Novo Nordisk's insulin degludec and liraglutide combination. ... In the EU, however, Xultophy has the edge as it received regulatory approval in 2014 in Europe, where it is marketed as IDegLira.

Latest news

  • Sanofi launches insulin combo Soliqua in US Sanofi launches insulin combo Soliqua in US

    Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... 2016. Xultophy is already available in Europe under the IDegLira trade name, but Novo Nordisk has not yet

  • FDA clears rival diabetes combos from Sanofi and Novo Nordisk FDA clears rival diabetes combos from Sanofi and Novo Nordisk

    FDA clears rival diabetes combos from Sanofi and Novo Nordisk. Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out. ... In the case of Xultophy, the combination is based on Novo's basal insulin Tresiba (insulin

  • Sanofi trumpets new IGlarLixi data after regulatory delay Sanofi trumpets new IGlarLixi data after regulatory delay

    Novo Nordisk's IDeglira/Xultophy (insulin degludec/liraglutide) is already on the market in Europe, but Sanofi had been hoping to get IGlarLixi to market in the US first with the ... Novo Nordisk is due to hear a verdict on Xultophy later this month.

  • Sanofi loses lead on diabetes combo IGlarLixi after FDA delay Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

    Sanofi loses lead on diabetes combo IGlarLixi after FDA delay. FDA verdict on Novo Nordisk’ s rival combo Xultophy due next month . ... The FDA is due to deliver a verdict on Xultophy next month, with a decision on IGlarLixi now pushed out to the end

  • Novo Nordisk's Tresiba gaining ground in basal insulin market Novo Nordisk's Tresiba gaining ground in basal insulin market

    Nevertheless, the strong sales performance for Tresiba and other new insulin products - such as combination products Ryzodeg (insulin degludec/insulin aspart) and Xultophy (insulin degludec/liraglutide) - helped Novo Nordisk post a

More from news
Approximately 13 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics